
Stoxx 600, FTSE, DAX, data
LONDON — Shares of Danish pharmaceutical giant Novo Nordisk were 3% higher in early deals Monday, after the company released trial data suggesting its blockbuster drug Wegovy outperforms major rivals in heart disease risk reduction. The study found continued users of semaglutide, a weight management drug branded as Wegovy, had up to a 57% greater reduction…